Download KARIM NASIRUDDIN JAMAL

KARIM N. JAMAL, MD
Present Address
3133 E Claremont
Phoenix, AZ 85016
(602) 363-1001
[email protected]
Business Address
1101 E Missouri Ave
Phoenix, AZ 85014
(602) 222-2221
EMPLOYMENT
Vitreoretinal Surgeon, Retinal Consultants of Arizona; Phoenix, AZ. July 2009—present
Vitreoretinal Surgeon, The Mayo Clinic; Scottsdale, AZ. September 2009—October 2010
TRAINING
Fellowship, Vitreoretinal Surgery; Texas Retina Associates; Dallas, TX. June 2007—June 2009
Residency, Ophthalmology; Case Western Reserve University; Cleveland, OH. July 2004—June 2007
Transitional Year Internship, Wilson Memorial Hospital; Johnson City, NY. July 2003—June 2004
EDUCATION
M.D.
B.A.
LICENSING
Arizona Medical License #41066
Texas Medical License #M7299
DEA current
HOSPITAL
APPOINTMENTS
Mayo Clinic; Scottsdale, AZ
Phoenix Children’s Hospital; Phoenix, AZ
Scottsdale Osborn Hospital; Scottsdale, AZ
Banner Gateway Hospital; Mesa, AZ
PROFESSIONAL
MEMBERSHIPS
American Society of Retina Specialists, 2009
Arizona Ophthalmologic Society, 2009
Phoenix Ophthalmologic Society, 2009
American Academy of Ophthalmology, 2004
PUBLICATIONS
Jamal KN, Dugel PU. Essential Diagnostic Devices for Retina Specialists. Cataract and Refractive Surgery
Today 2011 May; 22-4.
The University of Texas Southwestern Medical Center, Dallas, TX; August 1999—May 2003
Rice University, Houston, TX; August 1995—May 1999
Majors: Biochemistry and Managerial Studies
St. Joseph’s Hospital; Phoenix, AZ
Phoenix Baptist Hospital; Phoenix, AZ
Summit Healthcare; Show Low, AZ
Chen C, Jamal KN, Anand RA, Hogan RN. Aggressive Amelanotic Choroidal Melanoma with
Extrascleral Extension after successful Brachytherapy. Retina Cases & Brief Reports. 2010 Sep.)
Jamal KN, Dugel PU. IOL fixation techniques: the case for ACIOL. Retinal Physician 2009 Oct.
Jamal KN, Callanan DG. The Role of Difluprednate Ophthalmic Emulsion in Clinical Practice. Clin
Ophthalmol 2009:3 381–390.
Jamal KN, Goldenberg DT, Dugel PU. Causes and Treatment of Pseudophakic Cystoid Macular Edema.
Rev Ophthalmol. 2009 Apr; 16(4):92.
Jamal KN, Callanan DG. Presumed Ocular Histoplasmosis Syndrome. In: Gupta A, Gupta V, Herbort CP,
Khairallah M, editors. Uveitis: Text and Imaging. Maryland Heights: Jaypee Brothers, 2008: 654-660.
Ritch R, Jamal KN, Gurses-Ozden R, Liebmann JM. An improved technique of eye drop selfadministration for patients with limited vision. Am J Ophthalmol. 2003 Apr;135 (4):530-3.
Jamal KN, Gurses-Ozden R, Liebmann JM, Ritch R. Attempted eyelid closure affects intraocular pressure
measurement in open-angle glaucoma patients. Am J Ophthalmol. 2002 Aug;134 (2):186-9.
Jamal K, Carter-Dawson L. Increase in Vitreal Glutamate in Glaucoma Not Linked to Damaged Müller
Cells, Based on 3D Images. University of Texas-Houston Health Science Center, Summer Research
Program, Student Abstracts, Vol. X, p. 26, 1998.
PRESENTATIONS Jamal KN. Surgical Management of Massive Submacular Hemorrhages. Vit-Buckle Society Annual
Meeting; Las Vegas, NV; March 15, 2014
Jamal KN. New Therapeutic Approaches in Diabetic Macular Edema. Central Arizona Optometric
Society; February 11, 2014
Jamal KN. New Treatments in Wet Age-Related Macular Degeneration. Central Arizona Optometric
Society; February 19, 2013
Jamal KN. Approaches to Diabetic Macular Edema. Alcon meeting; Phoenix, AZ; April 30, 2012
Jamal KN. New Developments in Age-Related Macular Degeneration. Central Arizona Optometric
Society; February 21, 2012
Jamal KN. Treatment of Diabetic Macular Edema. Abbott meeting; Phoenix, AZ; May 11, 2011
Jamal KN. Clinical Trials Update. Foundation for Fighting Blindness; Phoenix, AZ; May 7, 2011
Jamal KN. Valentines and Vein Occlusions. Central Arizona Optometric Society, February 15, 2011
Jamal KN. A Brief History of Retinal Surgery. COA/COT CME meeting, Phoenix, AZ, January 15, 2011
Jamal KN. Retinal Surgery Evolutions. Arizona State University, Tempe, AZ, November 3, 2010
Jamal KN. New technology in Retinal surgery. American Society of Ophthalmic Registered Nurses
meeting, Flagstaff, AZ, May 21, 2010.
Tong W, Kidd M, Carey E, Jamal K, Charles J. Cholangiocarcinoma with Bilateral Retinal Detachments:
A Case Report and Literature Review. Society of Hospital Medicine Annual Meeting, Washington, DC,
April 8, 2010.
Jamal KN. Update on Diabetic Macular Disease. Horizon Eye CME, Phoenix, AZ, April 6, 2010
Jamal KN. AMD and Ocular Nutrition. Macular Vision Research Foundation, Gilbert, Arizona, February
27, 2010.
Jamal KN. Diabetic Macular Edema, Central Arizona Optometric Society, December 8, 2009
Jamal KN. Age-Related Macular Degeneration: An overview and update. The annual Vision Rehabilitation
and Technology Exposition, Mesa, Arizona, November 14, 2009.
Williams PD, Jamal KN, Callanan DG. Intravitreal Bevacizumab and Reduced-Fluence Photodynamic
Therapy for Choroidal Neovascularization due to Ocular Histoplasmosis Syndrome. American Society of
Retina Specialists Annual Meeting, Maui, Hawaii, October 12, 2008.
Jamal KN, Callanan DG. Anecortave Acetate in Eyes with Steroid-Induced Ocular Hypertension
Inadequately Controlled With Topical Intraocular Pressure-Lowering Medications. American
Society of Retina Specialists Annual Meeting, Maui, Hawaii, October 14, 2008.
Jamal K. Hope for Submacular Hemorrhage? Vitreoretinal Disease Update 2008, presented by Texas
Retina Associates, Dallas, Texas, May 18, 2008.
Jamal K, Rao L, Seffo F, Ward M, Huang S. Quality of Life and Cost-Effectiveness in Retinal Disease.
Case Western Reserve University Department of Ophthalmology Resident Research Day, June 16, 2006.
Rao L, Ward M, Seffo F, Jamal K, Huang S. Complications of 25g Vitrectomy Surgery in a Preliminary
Series: A Comparative Analysis of the Learning Curve Effect. ARVO program #4663, May 3, 2006.
Ward M, Rao L, Seffo F, Jamal K, Huang S. Visual Recovery in Patients Undergoing 25g
Transconjunctival Vitrectomy. ARVO program #4646, May 3, 2006.
Jamal K, Huang S. “New” Scotoma in a 55 year-old Male. Case Western Reserve University Department
of Ophthalmology Grand Rounds, January 11, 2006.
Jamal K. Sudden Loss of Vision in an African-American Male. Case Western Reserve University
Department of Ophthalmology Grand Rounds, September 21, 2005.
Jamal K, Thomas J. Refractive Surgery in the Thin Cornea. Case Western Reserve University Department
of Ophthalmology Resident Research Day, June 24, 2005.
Jamal K, Tomsak R. Amaurosis Fugax in a 14 year-old Girl. Case Western Reserve University
Department of Ophthalmology Grand Rounds, February 16, 2005.
Ritch R, Gurses-Ozden R, Jamal K, Liebmann JM: An improved technique for eyedrop administration.
4th International Symposium of Ophthalmology, Shantou, China, June 28, 2002.
CURRENT
CLINICAL
RESEARCH
A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety and Tolerability
of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular
Degeneration. Regeneron Pharmaceuticals. Protocol VGFT-OD-0605. Sub-Investigator. 2009-Present
A Randomized, Prospective, Active Controlled, Study of the Epi-Rad90 Ophthalmic System for the
Treatment of Subfoveal Choroidal Neovascularization Associated with Wet Age-Related Macular
Degeneration. NeoVista Inc. Protocol NVI-114-003. Sub-Investigator. 2009-Present
Comparison of Age-Related Macular degeneration Treatments Trials. National Eye Institute. Protocol
CATT. Sub-Investigator. 2009-Present
A Phase III, Double-Masked, Multi-Center, Randomized, Sham-Controlled Study of the Efficacy and Safety
of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement
Secondary to Diabetes Mellitus. Genentech Inc. Protocol FVF4170g. Sub-Investigator. 2009-Present
Study medication for Edema of the Macula in Diabetes: A Phase 2 Study. John Hopkins University.
Protocol READ-2. Sub-Investigator. 2009-Present
A 26-Week, Open-Label Study to Assess the Safety and Efficacy of 700 µg Dexamethasone Posterior
Segment Drug Delivery System Applicator System in the Treatment of Vitrectomized Subjects with
Diabetic Macular Edema. Allergan. Protocol 206207-018. Sub-Investigator. 2009-2010
A 26-Week, Open-Label Study to Assess the Safety and Efficacy of 700 µg Dexamethasone Posterior
Segment Drug Delivery System Applicator System as Adjunctive Therapy to Lucentis® in the Treatment of
Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Allergan.
Protocol 206207-019. Principal Investigator. 2009-2010
A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of
Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal
Vein Occlusion. Genentech. Protocol FVF4165g. Sub-Investigator. 2009-2010
A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of
Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Central Retinal
Vein Occlusion. Genentech. Protocol FVF4166g. Sub-Investigator. 2009-2010
A randomized, double-masked, placebo-controlled, add-on study to assess the efficacy of oral aliskiren 300
mg once daily for diabetic macular edema. Novartis Pharmaceutical Corp. Protocol CSPP100A2244. SubInvestigator. 2009-2011
A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the
Safety and Efficacy of Subconjunctival Injections of Sirolimus in Patients with Diabetic Macular Edema
Secondary to Diabetic Retinopathy. MacuSight Inc. Protocol DR-002. Sub-Investigator. 2009-2010
A PHASE ½, Randomized Clinical Study to Assess the Safety and Efficacy of Sirolimus in Patients with
Newly Diagnosed, Treatment Naive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related
Macular Degeneration. MacuSight Inc. Protocol AMD-002. Sub-Investigator. 2009-2010
A Phase II Prospective, Randomized, Multi-Center, Diabetic Macular Edema Dose Ranging, Comparator
Study Evaluating The Efficacy and Safety of PF-04523655 Versus Laser Therapy. Pfizer Inc. Protocol
B0451004. Sub-Investigator. 2009-2010
A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization
Associated with Wet Age-Related Macular Degeneration in Patients that Require Persistent Anti-VEGF
Therapy. NeoVista Inc. Protocol NVI-008. Sub-Investigator. 2009-Present.
An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability Of Ranibizumab In
Subjects With Choroidal Neovascularization (CNV) Secondary To Age-Related Macular Degeneration
(AMD) of Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed A
Genentech-Sponsored Ranibizumab Study. Genentech. Protocol FVF3426g. Sub-Investigator. 20092010.
A Phase 2, Randomized, Masked, Controlled Clinical Study to Assess the Safety and Efficacy of Lucentis
plus Sirolimus versus Lucentis plus Placebo in Patients with Sub-Foveal Choroidal Neovascularization
Secondary to Age-Related Macular Degeneration. MacuSight Inc. Protocol AMD-003. Sub-Investigator.
2009-2010.
A Randomized, Placebo Controlled, Double-Masked, Multicenter Trial of Microplasmin for Intravitreal
Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. ThromboGenics Inc. Protocol
TG-MV-006. Sub-Investigator. 2009-2010
A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of
Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to
Central Retinal Vein Occlusion (CRVO). Regeneron. Protocol VGFT-OD-0819. Sub-Investigator. 2009Present
A Multicenter, Masked, Randomized, Sham-Controlled, Parallel-Group, 3 Month Study with a 9-Month
Safety Extension to Evaluate the Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug
Delivery System (Brimonidine Tartrate PS DDS®) Applicator System in Improving Visual Function in
Patients with a Previous Rhegmatogenous Macula-Off Retinal Detachment. Allergan Inc. Protocol
190342-031D. Sub-Investigator. 2010-Present
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage due to Proliferative Diabetic
Retinopathy. DRCRNet. Protocol N. Sub-Investigator. 2010-Present
A 12-Month, Multicenter, 2-Stage (Open Label, Dose-Escalation, Followed by Masked, Randomized)
Single Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME)
Associated with Retinal Vein Occlusion (RVO). Allergan. Protocol 208397-001. Sub-Investigator. 2010Present
A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of
Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination with Lucentis®
in Subjects with Neovascular Age-Related Macular Degeneration. Ophthotech. Protocol OPH1001.
Principal Investigator. 2010-present
A Phase 2b Dose-Finding Study of Pazopanib Eye Drops versus Ranibizumab Injections for the Treatment
of Neovascular Age-Related Macular Degeneration. GlaxoSmithKline. Protocol MD7110852. SubInvestigator. 2010-present
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab
in Subjects with Inactive Non-infectious Intermediate-, Posterior-, or Pan-uveitis. Abbott Laboratories.
Protocol M10-880. Sub-Investigator. 2010-present
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab
as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious
Intermediate-, Posterior-, or Pan-uveitis. Abbott Laboratories. Protocol M10-877. Sub-Investigator. 2010present
A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF
Monoclonal Antibody Adalimumab in Subjects with Non-infectious Intermediate-, Posterior-, or Panuveitis. Abbott Laboratories. Protocol M11-327. Sub-Investigator. 2010-present
A 12-Month, Multicenter, Masked, Randomized, Controlled Study to Assess the Safety and Efficacy of 700
μg Ozurdex® (700 μg Dexamethasone) as Adjunctive Therapy to Lucentis® Compared with Lucentis®
Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-related Macular
Degeneration. Allergan. Protocol 206207-021. Principal Investigator. 2010-2011
A Phase I, Open-Label, Multi-Center, Dose Escalating, Safety and Tolerability Study of a Single
Intravitreal Injection of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration.
Genzyme. Protocol sFLT01-AMD-00106. Sub-Investigator. 2010-present
A Phase I, Open-label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to
Patients with Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic
Neuropathy (NAION) (Stratum II). Quark Pharmaceuticals. Protocol QRK.007. Sub-Investigator. 2011present
A multicenter, open label, single ascending dose study to assess the safety, tolerability, and serum
pharmacokinetics of intravitreal LFG316 in patients with advanced age-related macular degeneration.
Novartis. Protocol LFGJ316A2102. Sub-Investigator. 2011-2011
A Multi-center, Double-Masked, Parallel Group, Placebo-Controlled Study to Assess the Efficacy and
Safety of Voclosporin as Therapy in Subjects with Active Noninfectious Intermediate, Posterior or Panuveitis. Lux Biosciences, Inc. Protocol LX211-11. Sub-Investigator. 2011-present
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation, Multiple-Dose Study of
the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects with Dry AgeRelated Macular Degeneration (Geographic Atrophy). Acucela. Protocol 4429-201. Sub-Investigator. 2011present
A phase 2, multi-center, randomised, double-masked, placebo-controlled, parallel-group study to investigate
the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in adult patients
with geographic atrophy (GA) secondary to age-related macular degeneration. GlaxoSmithKline.
BAM114341. Sub-Investigator. 2011-present
Effect of Diabetes Education during Retinal Ophthalmology Visits on Diabetes Control. DRCRNet.
Protocol M. Principal Investigator. 2011-present
Safety and Efficacy Study of ESBA1008 versus LUCENTIS® for the Treatment of
Exudative Age-Related Macular Degeneration. Alcon. Protocol C-10-083. Sub-Investigator. 2011-present
A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and
Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious
Uveitis of the Posterior Segment of the eye. Santen. Protocol 32-007. Sub-Investigator. 2011-present
A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of
Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema. Regeneron.
Protocol VGFT-OD-1009. Sub-Investigator. 2011-present
Single and Repeat Dose Study of the Safety and Efficacy of AGN-150998 in Patients with Exudative Agerelated Macular Degeneration. Allergan. Protocol 150998-001. Sub-Investigator. 2011-present
A Randomized, Sham-Controlled, Double-Masked, Multicenter Trial Evaluating Ocriplasmin Treatment for
Symptomatic Vitreomacular Adhesion Including Macular Hole. ThromboGenics. Protocol TG-MV-O14.
Sub-Investigator. 2011– present
A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo-controlled, Parallel Group Study
to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (1% and
2%) Twice Daily for the Treatment of Center-involving Clinically Significant Macular Edema Associated
with Diabetic Retinopathy. Fovea SA. Protocol FOV2304/CLlN12011P. Sub-Investigator. 2011 - 2012.
A Multicenter, Randomized, Sham-Control, Proof-of-Concept Study of Intravitreal LFG3 16 in Patients
with Geographic Atrophy Associated with Age-Related Macular Degeneration. Novartis. Protocol
CLG316A2203. Sub-Investigator. 2011– present
A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700ug
Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients
With Diabetic Macular Edema. Allergan. Protocol 206207-024. Sub-Investigator. 2012 – present
A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated
Intravitreal injections of iCo-007 as Monotherapy or in Combination with Ranibizumab or Laser
Photocoagulation in the Treatment of Diabetic Macular Edema with Involvement of Foveal Center.
1DRF/Quan Dong Nguyen, MD, MSc. Protocol 20 10-007-03-DME. Sub-Investigator. 2012 – present
An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined with a Prospective,
Randomized, Double-Masked, Multicenter Controlled Study (Stratum II) Evaluating the Efficacy and
Safety of PF-04523655 Alone and in Combination with Ranibizumab Versus Ranibizumab Alone in
Diabctic Macular Edema. Quark Pharmaceuticals. Protocol QRK202. Sub-Investigator. 2012 – 2013
A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of
Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibcrcept Injection [IAI] in Patients with
Macular Edema Secondary to Branch Retinal Vein Occlusion. Regeneron. Protocol VOFTe-RVO-I027.
Sub-Investigator. 2012 – present
Prompt Panretinal Photocoagulation versus Intravitreal Ranibizumab With Deferred Panretinal
Photocoagulation for Proliferative Diabetic Retinopathy. DRCRNet Protocol S. Principal Investigator.
2012 – present
A Multicenter, Randomized, Single-Masked, Sham-Controlled, Proof-Of-Concept Study of Intravitreal AL78898A In Patients With Bilateral Geographic Atrophy (GA) Associated With Age-Related Macular
Degeneration (AMD). Alcon. Protocol C-12-020. Sub-Investigator. 2012 – 2012
Safety Assessment and Therapeutic Effect of Non-Damaging Patterned Scanning Laser Phototherapy in
Patients with Diffuse Diabetic Macular Edema. Investigator-Sponsored Trial with Topcon. Protocol
PASCAL2012. Sub-Investigator. 2012 – 2013
A Phase 2a, Multi-Center, Masked, Randomized. Comparator-Controlled Study Evaluating iSONEP
(sonepcizumab (LTl009]) as Either Monotherapy or Adjunctive Therapy to Lucentis® or Avastin® versus
Lucentis or Avastin Alone for the Treatment of Subjects with Choroidal Neovascularization Secondary to
Age-Related Macular Degeneration. Lpath. Protocol LTI009-0ph-003. Sub-Investigator. 2012 – present
A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in
Patients with Diabetes Mellitus. Investigator-Sponsored Trial with Allergan. Protocol RCA2012.
SubInvestigator. 2012 - present
A Phase 2b/3 Randomized, Double-Masked, Dose-Ranging, Multicenter Study Comparing the Efficacy and
Safety of ACU-4429 with Placebo for the Treatment of Geographic Atrophy Associated with Dry AgeRelated Macular Degeneration. Acucela Protocol 4429-202. Sub- Investigator. 2013 - present
A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and
Safety of ESBA 1008 versus EYLEA® in Subjects with Exudative Age-Related Macular Degeneration.
Alcon protocol C-12-006. Sub-Investigator. 2013 – present
A multicenter, open-label, single ascending dose study to assess the safety, tolerability, and serum
pharmacokinetics of intravitreal CLG561 in subjects with advanced age-related macular degeneration.
Alcon protocol C-12-074. Sub-Investigator. 2013 – present
A clinical trial to assess the impact of home monitoring to decrease the treatment burden for Neovascular
Macular Degeneration (the LIBERTY study). An Investigator-sponsored trial with Genentech. Protocol
ML28727. Sub-Investigator. 2013 – present
A Phase 3, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy
Study of a Flucinolone Acetonide Intravitreal (FAI) Insert in Subjects with Chronic Non-Infectious Uveitis
Affecting the Posterior Segment of the Eye. pSivida protocol PSV-FAI-001. Sub-Investigator. 2013-present
A Phase 3, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of
Intravitreous Administration of Fovista™ (Anti-PDGF-B Pegylated Aptamer) Administered in Combination
with Lucentis Compared to Lucentis Monotherapy In Subjects with Subfoveal Neovascular Age-Related
Macular Degeneration. Ophthotech OPH 1002. Principal Investigator. 2013 – present
A Prospective, Two Cohort, Single-Masked Study to Evaluate the Effect of ESBA 1008 Applied by
Microvolume Injection or Infusion in Subjects with Exudative Age-Related Macular Degeneration. Alcon
protocol C-13-001. Sub-Investigator. 2013 – present
HONORS AND
DISTINCTIONS
CRCA America’s Top Ophthalmologists; 2011, 2012, 2013, 2014
Leading Physicians of the World, 2011
Cambridge Who's Who Registry of Executives, Professionals, and Entrepreneurs, 2009
Aga Khan Education Board Professional Achievement Award, 2009 and 2010
1st Place Overall, Basic and Clinical Science Course Examination Series, 2006-2007
1st Place PGY-3 Level, Basic and Clinical Science Course Examination Series, 2005-2006
Alpha Omega Alpha, 2003
Honors in Advanced Ophthalmology clerkship at Massachusetts Eye and Ear Infirmary/Harvard, 2002
Honors in Ophthalmology clerkship at University of Texas Southwestern, 2002
ARVO/Weisenfeld Albert G. Mosler Student Fellowship Grant Award, 2000
Wiess College Senior Service Award, one of five recipients honored for service to the student body, 1999
Wiess College Fellow, 1998
President’s Honor Roll, Rice University, 1995-1998
LEADERSHIP
EXPERIENCE
Resident Representative in establishment of senior surgical rotation at LV Prasad Eye Institute; 2005-6
Principal, Cleveland Ismai’li Religious Education Center; 2005-2007
Internal Vice President, Wiess College, Rice University; 1998
Co-founder, Wiess College Mentors volunteer tutoring program, Rice University; 1998
Chair, Wiess College Elections Committee; 1997
PREVIOUS
EMPLOYMENT
Teaching Assistant, Neuroscience & Physiology, Univ. Texas Southwestern Medical School; spring 2003
Teaching Assistant, Cell Biology, Univ. Texas Southwestern Medical School; spring 2003
Lounge Staff, Major Tom’s Pub, Dublin, Ireland; summer 1995
Dishwasher, The Bad Ass Café, Dublin, Ireland; summer 1995
ARTISTIC
EXPERIENCE
Assistant Producer/Writer, “Oatmeal in Fifteen Minutes,” full-length original screenplay; 2002-2003
Staff writer, The Murmur, a Univ. Texas Southwestern humor magazine; 2001-2002
Filmographer/Editor/Co-Producer, “Lost in a K-hole,” documentary; 1999
Bass Guitarist, Edloe Street, rock band; 1998-1999
Co-founder and Bass Guitarist, Riot Nrrrd, rock band; 1997-1999
Disc Jockey, 90.5 FM WHRW Binghamton; summers of 1994 and 1995